Last reviewed · How we verify
HGF Plasmid
At a glance
| Generic name | HGF Plasmid |
|---|---|
| Also known as | AMG0001 |
| Sponsor | AnGes USA, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial (PHASE2)
- Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (PHASE2)
- Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea (PHASE2)
- Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2) (PHASE3)
- Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1) (PHASE3)
- Angiogenesis and Blood Perfusion Effect of HGF Gene Therapy in PAD Patients (PHASE3)
- Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers (PHASE2)
- Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HGF Plasmid CI brief — competitive landscape report
- HGF Plasmid updates RSS · CI watch RSS
- AnGes USA, Inc. portfolio CI